TDOC at a glance
Teladoc Health, Inc. (TDOC, SEC CIK 1477449) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 25, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Teladoc Health, Inc. (TDOC) reported revenue of $2.5 billion (down 1.5% from FY2024) and a net loss of $200.3 million. Diluted EPS was -$1.14.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Teladoc Health, Inc. (TDOC) shares worth $636.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Catapano Joseph Ronald on October 2, 2026 of 655 shares at $5.65 per share.
- In the last 90 days, TDOC insiders reported 0 open-market purchases ($0) and 9 open-market sales ($461K) on Form 4, a net sale of $461K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.5B
- −1.5% vs prior year
- Insiders · 90 days
- 0 buys · 9 sells
- Net −$461K
- 13F holders
- 32 funds
- $636.9M · −1 vs prior quarter
- Latest 8-K
- Sep 25, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Global virtual care leader offering integrated healthcare services via technology platforms to employers, health plans, and individuals
- New emphasis on AI-enhanced capabilities: Advanced AI-driven predictive analytics, personalized engagement, and AI-enabled clinical documentation improvements launched in Prism platform
- Strategic shift to integrated mental health: Expanded mental health services fully embedded across longitudinal care programs and national rollout of insurance coverage acceptance for BetterHelp
- Notable metric: Access for approximately 102 million U.S. members, with 17.1 million telehealth visits completed in 2025 across B2B and D2C channels
- Unique fact: Established The Institute for Patient Safety and Quality of Virtual Care, first US-certified Patient Safety Organization dedicated to virtual care
Risk Factors
- Regulatory risk: Impact of Patient Protection and Affordable Care Act (PPACA) and related laws reducing Medicare payments up to 2% annually through 2030
- Geopolitical/macroeconomic threat: Revenue risk from potential Client mergers/acquisitions causing contract cancellations or non-renewals impacting 19% total revenue from top five Clients
- Operational/supply chain vulnerability: Dependence on limited third-party suppliers for timely materials access risks supply chain disruptions and cost inflation
- Competitive risk: Pricing pressure and market share loss from well-financed health plans and tech companies developing discounted competing virtual care services
- Financial risk: Accumulated deficit $16.4B with net losses $200.3M in 2025 and $1B in 2024; reliance on raising capital on uncertain terms to fund operations
Management Discussion & Analysis
- Revenue details for FY2025 vs FY2024 omitted; see 2024 10-K filed Feb 27, 2025 for full YoY analysis
- U.S. Integrated Care members +9% YoY, increased by 8.0 million to 101.8 million as of Dec 31, 2025
- Average monthly revenue per U.S. Integrated Care member down to $1.29 from $1.37 YoY, reflecting new member onboarding
- BetterHelp paying users declined 5% YoY to 0.39 million for year ended Dec 31, 2025
- $71.8 million goodwill impairments recorded in 2025 on Integrated Care acquisitions (Telecare, Catapult Health)
- Goodwill balance $283.2 million as of Dec 31, 2025, all in BetterHelp segment; no impairment recorded on annual test
- Amortization expense increased by $7.7 million in 2025 due to decreased useful life of trademarks; expects +$30.7 million in 2026
- Risks from tariffs on imported components could impact operations; continued evaluation ongoing
- Refunds on BetterHelp service $49.9 million in 2025 vs $84.0 million in 2024
- Seasonality noted: Integrated Care strong in Q1 and Q4; BetterHelp reduces marketing spend in Q4 causing weaker operating income in Q1
AI summary of the TDOC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $606.9M, down $25.0M or 4% YoY, driven by lower BetterHelp revenue
- Operating margin negative 6.1% vs negative 8.6% YoY
- Integrated Care best performer, Adjusted EBITDA $65.2M vs $57.5M; BetterHelp $0.5M vs $11.9M
- BetterHelp paying users 0.346M, down 11% from 0.388M YoY
- Outlook headwinds: declining cash-pay users, insurance-mix effects, tariffs, and potential BetterHelp goodwill impairment
Risk Factors
- BetterHelp insurance expansion shifting users from cash-pay services, reducing revenue and initial revenue recognition
- Provider credentialing capacity constrained insurance-covered demand, preventing offset of cash-pay revenue declines
- BetterHelp advertising and marketing spend reduced during Q2 2026, lowering acquired paying users and near-term revenue
- Higher customer-acquisition costs or weaker marketing effectiveness threatening BetterHelp revenue and profitability
- Insurance plans’ deductibles, copays, and restrictions complicating consumer adoption of BetterHelp coverage
AI summary of the TDOC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Legal Officer Adam C. Vandervoort resigns effective November 1, 2026, citing good reason under his severance agreement
- Vandervoort to provide unpaid transition advisory services through November 1, 2027
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Michael Grasher appointed CFO effective August 31, 2026, ending interim CFO arrangement while Charles Divita remains CEO
- $550,000 annual salary, $500,000 sign-on bonus, and 85% target annual bonus beginning 2027
Item 7.01: Regulation FD Disclosure
- Appointment of Mr. Grasher as Teladoc’s Chief Financial Officer
- CFO transition potentially affecting financial oversight, capital allocation, and investor communication
Item 5.02: Departure/Appointment of Directors or Principal Officers
- David B. Snow Jr. retiring from Teladoc’s Board effective September 30, 2026
- Snow served as a director since 2014, marking a substantial governance transition
AI summaries of TDOC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TDOC
Don't miss the next TDOC filing
- Alerts as it files. A push when TDOC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TDOC, by share count.
- Ask anything. An AI agent that reads every TDOC filing and answers with sources.
TDOC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Catapano Joseph Ronald | Sell | Oct 2, 2026 | 655 | $5.65 |
| Catapano Joseph Ronald | M | Oct 1, 2026 | 2,083 | - |
| Catapano Joseph Ronald | M | Oct 1, 2026 | 2,083 | - |
| DIVITA CHARLES III | Sell | Sep 11, 2026 | 17,805 | $6.10 |
| DIVITA CHARLES III | M | Sep 10, 2026 | 39,160 | - |
| DIVITA CHARLES III | M | Sep 10, 2026 | 3,642 | - |
| DIVITA CHARLES III | M | Sep 10, 2026 | 39,160 | - |
| DIVITA CHARLES III | M | Sep 10, 2026 | 3,642 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $2.6B | $2.6B | $2.5B |
| Operating Income | - | -$1.0B | -$263.0M |
| Net Income | -$220.4M | -$1.0B | -$200.3M |
| Op. Margin | - | -39.7% | -10.4% |
| Net Margin | -8.5% | -39.0% | -7.9% |
| Balance Sheet | |||
| Total Assets | - | $3.5B | $2.9B |
| Equity | - | $1.5B | $1.4B |
| ROE | - | -67.1% | -14.5% |
| Per Share | |||
| EPS | $-1.34 | $-5.87 | $-1.14 |
| Cash Flow | |||
| Operating CF | - | $293.7M | $294.4M |
| CapEx | $11.5M | $10.8M | $8.9M |
Source: XBRL data in Teladoc Health, Inc. (TDOC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TDOC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $636.9M |
| Q1 2026 | 33 | $374.7M |
| Q4 2025 | 31 | $510.3M |
| Q3 2025 | 31 | $600.1M |
| Q2 2025 | 31 | $627.7M |
| Q1 2025 | 27 | $471.1M |
| Q4 2024 | 23 | $417.2M |
| Q3 2024 | 21 | $209.6M |
- BlackRock+1.61M (+11%)
- Goldman Sachs Group+1.12M (+41%)
- Dimensional Fund Advisors+1.07M (+17%)
- FMR LLC (Fidelity)+730.4K (+2425%)
- AQR Capital Management+728.3K (+71%)
- Bank of America Corp−1.10M (-69%)
- JPMorgan Chase & Co−55.1K (-10%)
- D.E. Shaw & Co−42.0K (-6%)
- Marex Group plc−38.7K (-68%)
- Morgan Stanley−35.0K (-3%)
- Millennium Management+145.4K
- Mangrove Partners−104.4K
- M&T Bank−17.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 229 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TDOC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| SC 13G | Jun 22, 2026 | - | - | |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - |
Related Health Care companies
- AIRS · Airsculpt Technologies, Inc.Services-Offices & Clinics of Doctors of Medicine
- HIMS · Hims & Hers Health, Inc.Services-Offices & Clinics of Doctors of Medicine
- LFMD · LifeMD, Inc.Services-Offices & Clinics of Doctors of Medicine
- TOI · Oncology Institute, Inc.Services-Offices & Clinics of Doctors of Medicine
- SBC · SBC Medical Group Holdings IncServices-Offices & Clinics of Doctors of Medicine
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
TDOC SEC filings: frequently asked questions
Are TDOC insiders buying or selling?
In the last 90 days, Teladoc Health, Inc. (TDOC) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $460,877 by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TDOC stock?
As of June 30, 2026, the largest Teladoc Health, Inc. (TDOC) holders among the 13F filers tracked by SignalX were BlackRock ($137.6 million), Vanguard Portfolio Management LLC ($107.6 million), Renaissance Technologies LLC ($68.5 million), Vanguard Capital Management LLC ($67.5 million), Dimensional Fund Advisors ($62.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TDOC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Teladoc Health, Inc. (TDOC) reported revenue of $2.5 billion (down 1.5% from FY2024) and a net loss of $200.3 million. Diluted EPS was -$1.14. The figures come from the XBRL data in the 10-K.
What are the main risks in TDOC's latest 10-K?
In the 10-K filed February 26, 2026, Teladoc Health, Inc. (TDOC) flagged: Regulatory risk: Impact of Patient Protection and Affordable Care Act (PPACA) and related laws reducing Medicare payments up to 2% annually through 2030. Geopolitical/macroeconomic threat: Revenue risk from potential Client mergers/acquisitions causing contract cancellations or non-renewals impacting 19% total revenue from top five Clients. (AI summary of the Risk Factors section.)
What did TDOC report in its latest 8-K?
Teladoc Health, Inc. (TDOC) filed an 8-K on September 25, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Chief Legal Officer Adam C. Vandervoort resigns effective November 1, 2026, citing good reason under his severance agreement.
What are the latest TDOC SEC filings?
Teladoc Health, Inc. (TDOC) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 25, 2026 and a Form 4 insider filing on October 5, 2026.
What is TDOC's SEC CIK number?
Teladoc Health, Inc. (TDOC)'s SEC Central Index Key (CIK) is 1477449. EDGAR lists every TDOC filing under that number.
Ask anything about TDOC
The research agent reads TDOC's filings, financials, insider trades and 13F holders, then answers with sources.